Aprameya Engineering Ltd Q1 FY26 Earnings Analysis
Published 16 Jul 2026 | Healthcare Equipment & Supplies | Market Cap: ₹445 Cr
Price
₹150
Market Cap
₹445 Cr
P/E Ratio
18.1
Revenue Rank
Margin Rank
Earnings Summary
- Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade. - Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services.
📊 Revenue & Sales Performance
Rank 3- Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade. - The company is optimistic about securing good orders across multiple states due to its proprietary products and strong entry barriers in tenders. - With an expanding geographic footprint into states like Bihar, Uttarakhand, Assam, Chhattisgarh, Daman, and Sikkim, Aprameya is positioned for scalable growth. - Order book stood at INR 60 crores, with expectations for continuous order inflow driven by unique, lifesaving proprietary solutions. - Revenue grew by 108% YoY to INR 136 crores in FY25, backed by a higher share of high-margin turnkey projects. - Management expresses confidence in maintaining and improving margins and increasing service contracts, which contribute recurring revenue. - Future guidance hints at steady revenue growth, though no specific growth percentage is promised.
📈 Profitability & Margins
Rank 3- Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services. - The company is confident in maintaining current margin levels, focusing on high-margin projects and selective bidding. - EBITDA margin improved to 18% in FY25; this level is expected to be sustainable with disciplined cost and capital management. - PAT margin increased to 12% in FY25, reflecting operational efficiencies. - Growth driven by geographic expansion into underpenetrated states like Bihar, Assam, and Uttarakhand. - Expanding order book with INR60 crores executing over 5-6 months and targeting high-margin contracts. - Focus on increasing services and CMC contracts post three-year warranty completion, which have higher margins. - Entering specialized proprietary product markets (e.g., EP lab systems) to boost margins and revenues. - Cash flow improvements expected due to reducing debtor cycles. - Management confident in delivering sustained earnings growth but cautious on aggressive margin guidance without contract clarity.
🏗️ Capital Expenditure Plans
Yes- Capex for expansion into new states will be gradual, not a one-time large investment; focus is on brownfield projects (working inside existing buildings) rather than greenfield projects. - Capital investments in new states will be phased over 2-3 months per project rather than upfront heavy capital. - The company plans to control capex carefully to avoid hampering cash flow and maintain a balanced inflow and outflow ratio. - Specific capex figures are not shared publicly; investors are encouraged to contact the IR agency for detailed queries. - Debt levels have been declining year-on-year, and the company aims to manage working capital efficiently during expansion to avoid raising significant new debt. - Expansion will be selective, focusing only on projects where margins, revenue, and credit terms are comfortable to secure.
💰 Fundraising & Capital Structure
Yes- The management did not mention any specific plans for raising new debt or equity during the expansion. - They emphasized reducing the debtor cycle to improve cash flow and funding projects "as per our requirement only." - Capex for expansion will be gradual and aligned with cash inflows from ongoing projects, not requiring large upfront investments. - For exact capex figures or potential fundraising details, the management directed investors to contact their IR agency, Stellar, for specific queries. - The company aims to maintain manageable debt levels and has been successfully reducing net debt year-on-year. - Overall, the approach is cautious, focusing on operational cash flow and selective project bidding without immediate plans to raise significant external funds.
📋 Order Book & Pipeline
Yes- Current order book: Approximately INR 60 crores. - Execution timeline: Orders expected to be completed within 5 to 6 months. - Geographic split: 60%-70% from Maharashtra, 10%-20% from Rajasthan, remaining from Gujarat. - Growth outlook: Company optimistic about securing additional orders due to sector growth and strong entry barriers. - Previous projects and order pipeline suggest sustained opportunities for expansion across multiple states. - The company expects to maintain steady order inflow aligned with industry CAGR growth trends.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Aprameya Engineering Ltd Q1 FY26 results?
- Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade. - Aprameya aims to sustain strong growth, leveraging proprietary turnkey projects and expanding services.
What is Aprameya Engineering Ltd share price analysis?
Aprameya Engineering Ltd currently shows a below-average growth signal. The stock trades at a P/E of 18.1 with a market cap of ₹445. Investors should review the full earnings analysis for detailed insights.
Is Aprameya Engineering Ltd planning capital expenditure?
- Capex for expansion into new states will be gradual, not a one-time large investment; focus is on brownfield projects (working inside existing buildings) rather than greenfield projects.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
